Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of July 9, 2026, FATE trades at $3.06 with a market cap of $352.01M and a P/E ratio of -2.68. FATE moved +4.10% today. Year to date, FATE is +198.19%; over the trailing twelve months it is +168.81%. Its 52-week range spans $0.66 to $3.50. Analyst consensus is buy with an average price target of $5.24. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FATE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. FATE recently traded at $3.06. Market cap is $352.01M. P/E ratio is -2.68. Revenue is $6.32M.
| Metric | Value |
|---|---|
| Price | $3.06 |
| Market Cap | $352.01M |
| P/E Ratio | -2.68 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.50 |
| 52-Week Low | $0.66 |
| Volume | 1.85M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.32M |
| Net Income | $-129.91M |
| Gross Margin | 0.00% |
9 analysts cover FATE: 0 strong buy, 5 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.24.